LONG-TERM HEAVY CANNABIS USE LINKED TO THINNING IN FRONTAL BRAIN REGION

Contributed by: Presswire

Images

Presswire associated0

Tags

European Psychiatric Association

CANNABIS

More Like This

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

PR Newswire associated0

Curaleaf Report: Online and unregulated cannabis poses serious health risks with mould, lead, and synthetic cannabinoids detected

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

Gedeon Richter presents analysis on cannabis usage among patients with schizophrenia: a new medical solution to a severe issue might be available

PR Newswire associated0

NHS Access to Medical Cannabis Could Unlock £13.3bn and Return Thousands to Work

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Presswire associated0

GENETIC PREDISPOSITION TO ADHD LINKED TO ECONOMIC CHALLENGES ACROSS THE LIFE COURSE